medigraphic.com
ISSN 2070-8718 (Impreso)

2010, Número 3

<< Anterior Siguiente >>

Rev Cub Gen 2010; 4 (3)


Fisiopatología de la enfermedad renal poliquística

Rodríguez FRE, de la Nuez VA, López MN, Dávalos IJM

Idioma: Español
Referencias bibliográficas: 50
Paginas: 9-16
Archivo PDF: 291.13 Kb.


RESUMEN

La enfermedad renal poliquística es una de las condiciones genéticas con peligro para la vida más frecuentes en las poblaciones humanas. Se produce por mutaciones en los genes de algunas proteínas de las estructuras ciliares que modifica varias de las vías claves para la señalización celular, e induce un fenotipo hiperproliferativo que genera la aparición de neoplasmas benignos, localizados principalmente en el riñón, donde provocan la formación de quistes y la destrucción progresiva del tejido activo, hasta llegar a la enfermedad renal crónica. En los últimos años se ha acumulado una gran cantidad de información sobre la fisiopatología de la enfermedad y se ha hecho posible el surgimiento de estrategias nuevas para el tratamiento, que se encuentran en ensayos clínicos en todo el mundo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bisgrove BW, Yost HJ. The roles of cilia in developmental disorders and disease. Development. 2006;133(21):4131-4143.

  2. Moreno F, San Millan J, Viribay M, Ferreira R, Perai B, Bello D, et al. Genetic analysis of Cuban autosomal dominant polycystic kidney disease kindreds using RFLPs and microsatellite polymorphisms linked to the PKD1 locus. Hum Genet. 1994;94(4):432-436.

  3. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell. 1994;77(6):881-894.

  4. Rojas I, Davalos JM, Cendan I, Tamayo V, Perez E, Heredero L. Registro genético preventivo automatizado de la enfermedad poliquística renal autosómica dominante. Rev Cubana Invest Biomed. 1999;18(1):45-48.

  5. Rossetti S, Chauveau D, Walker D, Saggar-Malik A, Winearls CG, Torres VE, et al. A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int. 2002;61(5):1588-1599.

  6. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272(5266):1339-1342.

  7. Deltas CC. Mutations of the human polycystic kidney disease 2 (PKD2) gene. Hum. Mutat. 2001;18(1):13-24.

  8. Consugar MB, Wong WC, Lundquist PA, Rossetti S, Kubly VJ, Walker DL, et al. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int. 2008;74(11):1468-1479.

  9. Harris PC. 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery. J. Am. Soc. Nephrol. 2009;20(6):1188-1198.

  10. Zerres K, Mücher G, Becker J, Steinkamm C, Rudnik-Schöneborn S, Heikkilä P, et al. Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD): molecular genetics, clinical experience, and fetal morphology. Am. J. Med. Genet. 1998;76(2):137-144.

  11. Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat. Genet. 2002;30(3):259-269.

  12. Bergmann C, Senderek J, Sedlacek B, Pegiazoglou I, Puglia P, Eggermann T, et al. Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). J. Am. Soc. Nephrol. 2003;14(1):76-89.

  13. Gout AM, Martin NC, Brown AF, Ravine D. PKDB: Polycystic Kidney Disease Mutation Database--a gene variant database for autosomal dominant polycystic kidney disease. Hum. Mutat. 2007;28(7):654-659.

  14. Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, Kinter MT, et al. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev. Cell. 2006;10(1):57-69.

  15. Lal M, Song X, Pluznick JL, Di Giovanni V, Merrick DM, Rosenblum ND, et al. Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling. Hum. Mol. Genet. 2008;17(20):3105-3117.

  16. Bertuccio CA, Chapin HC, Cai Y, Mistry K, Chauvet V, Somlo S, et al. Polycystin-1 C-terminal cleavage is modulated by polycystin-2 expression. J. Biol. Chem. 2009;284(31):21011-21026.

  17. Markoff A, Bogdanova N, Knop M, Rüffer C, Kenis H, Lux P, et al. Annexin A5 interacts with polycystin-1 and interferes with the polycystin-1 stimulated recruitment of E-cadherin into adherens junctions. J. Mol. Biol. 2007;369(4):954-966.

  18. Boca M, D’Amato L, Distefano G, Polishchuk RS, Germino GG, Boletta A. Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent cell cell mechanical adhesion. Mol. Biol. Cell. 2007;18(10):4050-4061.

  19. Mostov KE. mTOR is out of control in polycystic kidney disease. Proc. Natl. Acad. Sci. U.S.A. 2006;103(14):5247-5248.

  20. Celić A, Petri ET, Demeler B, Ehrlich BE, Boggon TJ. Domain mapping of the polycystin-2 C-terminal tail using de novo molecular modeling and biophysical analysis. J. Biol. Chem. 2008;283(42):28305-28312.

  21. Fu X, Wang Y, Schetle N, Gao H, Pütz M, von Gersdorff G, et al. The subcellular localization of TRPP2 modulates its function. J. Am. Soc. Nephrol. 2008;19(7):1342-1351.

  22. Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, et al. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature. 2000;408(6815):990-994.

  23. Koulen P, Cai Y, Geng L, Maeda Y, Nishimura S, Witzgall R, et al. Polycystin-2 is an intracellular calcium release channel. Nat. Cell Biol. 2002;4(3):191-197.

  24. Tsiokas L, Kim E, Arnould T, Sukhatme VP, Walz G. Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc. Natl. Acad. Sci. U.S.A. 1997;94(13):6965-6970.

  25. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 2003;33(2):129-137.

  26. Boletta A, Qian F, Onuchic LF, Bhunia AK, Phakdeekitcharoen B, Hanaoka K, et al. Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol. Cell. 2000;6(5):1267-1273.

  27. Zhang M, Mai W, Li C, Cho S, Hao C, Moeckel G, et al. PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2004;101(8):2311-2316.

  28. Hiesberger T, Gourley E, Erickson A, Koulen P, Ward CJ, Masyuk TV, et al. Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C. J. Biol. Chem. 2006;281(45):34357- 34364.

  29. Kim I, Fu Y, Hui K, Moeckel G, Mai W, Li C, et al. Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J. Am. Soc. Nephrol. 2008;19(3):455-468.

  30. Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, et al. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell. 2002;109(2):157-168.

  31. Liang G, Yang J, Wang Z, Li Q, Tang Y, Chen X. Polycystin-2 down-regulates cell proliferation via promoting PERKdependent phosphorylation of eIF2alpha. Hum. Mol. Genet. 2008;17(20):3254-3262.

  32. Edelstein CL. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol. 2008;3(4):1219-1226.

  33. Simons M, Gloy J, Ganner A, Bullerkotte A, Bashkurov M, Krönig C, et al. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat. Genet. 2005;37(5):537-543.

  34. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 2004;10(4):363-364.

  35. Héliès-Toussaint C, Aarab L, Gasc JM, Verbavatz JM, Chabardès D. Cellular localization of type 5 and type 6 ACs in collecting duct and regulation of cAMP synthesis. Am. J. Physiol. Renal Physiol. 2000;279(1):F185-194.

  36. Ang K, Antoni FA. Reciprocal regulation of calcium dependent and calcium independent cyclic AMP hydrolysis by protein phosphorylation. J. Neurochem. 2002;81(3):422-433.

  37. Yamaguchi T, Hempson SJ, Reif GA, Hedge A, Wallace DP. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J. Am. Soc. Nephrol. 2006;17(1):178-187.

  38. Li H, Findlay IA, Sheppard DN. The relationship between cell proliferation, Cl- secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int. 2004;66(5):1926-1938.

  39. Gresh L, Fischer E, Reimann A, Tanguy M, Garbay S, Shao X, et al. A transcriptional network in polycystic kidney disease. EMBO J. 2004;23(7):1657-1668.

  40. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J. Biol. Chem. 2004;279(39):40419-40430.

  41. Torres VE. Vasopressin antagonists in polycystic kidney disease. Semin. Nephrol. 2008;28(3):306-317.

  42. Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J. Intern. Med. 2007;261(1):17-31.

  43. Torres VE, Sweeney WE, Wang X, Qian Q, Harris PC, Frost P, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int. 2003;64(5):1573-1579.

  44. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. U.S.A. 2006;103(14):5466-5471.

  45. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press. Res. 2007;30(4):253-259.

  46. Boletta A. Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics. 2009;2(1):6-22.

  47. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol. Cell. Biol. 2009;29(9):2359-2371.

  48. Weimbs T. Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. Am. J. Physiol. Renal Physiol. 2007;293(5):F1423-1432.

  49. Walz G. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Nephrol. Dial. Transplant. 2006;21(7):1752-1757.

  50. Serra AL, Kistler AD, Poster D, Struker M, Wüthrich RP, Weishaupt D, et al. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol. 2007;8:13.




2020     |     www.medigraphic.com